| LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer (NCT04616183) | M.D. Anderson Cancer Center | 2020-12-02 |
| Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer (NCT04017650) | M.D. Anderson Cancer Center | 2019-06-14 |
| Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia (NCT03823079) | Fudan University | 2019-02-01 |
| Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver (NCT03403634) | Roswell Park Cancer Institute | 2018-04-19 |
| Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer (NCT03095781) | Emory University | 2017-07-07 |
| Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer (NCT02873195) | Academic and Community Cancer Research United | 2017-07-07 |
| APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery (NCT03087591) | Wake Forest University Health Sciences | 2017-04-28 |
| Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery (NCT02738606) | M.D. Anderson Cancer Center | 2016-09-23 |
| Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery (NCT02713373) | Roswell Park Cancer Institute | 2016-08-05 |
| FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer (NCT02508077) | City of Hope Medical Center | 2016-02-16 |
| TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors (NCT02650635) | Mayo Clinic | 2016-02-05 |
| Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas (NCT02973672) | Surgimab | 2016-01-01 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060) | National Cancer Institute (NCI) | 2015-08-17 |
| Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer (NCT02188264) | National Cancer Institute (NCI) | 2014-08-29 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533) | National Cancer Institute (NCI) | 2012-08-03 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (NCT01522820) | Roswell Park Cancer Institute | 2012-03-01 |
| Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" (NCT01365169) | M.D. Anderson Cancer Center | 2011-05-25 |
| Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma (NCT00545545) | HiberCell, Inc. | 2007-10-01 |